Iranian journal of Pediatric Hematology and Oncology

en Overexpression of the IL-33/ST2 in Pediatric Acute Lymphoblastic Leukemia: Evaluation of the Effects of a Treatment Program انکولوژی Oncology پژوهشي Research <div style="border: 1.5pt double windowtext; padding: 1pt 4pt; text-align: justify;">Background: The study focuses on B-acute lymphoblastic leukemia (B-ALL), a common childhood blood cancer marked by an overproduction of B lymphocytes. It explores the role of cytokine expression changes, particularly Interleukin-33 (IL-33), which has both anti- and pro-tumor effects. The research assesses the expression of IL-33 and its receptor, suppression of tumorigenicity 2 (ST2), in B-ALL patients before and after chemotherapy treatment. Materials and Methods: In this quasi-experimental investigation, peripheral blood specimens were taken from 33 newly-diagnosed/untreated ALL patients. An induction chemotherapy course was administered to ALL patients for 30 days following diagnosis. Blood samples were taken again after the completion of induction chemotherapy. 30 healthy individuals with matched age and gender were also recruited as a control group. Serum IL-33 quantities were assessed using the ELISA method. Total RNA was extracted from peripheral blood samples, and the gene expression of IL33 and ST2 was measured using real-time PCR. Results: In B-ALL patients, the pre-treatment serum IL-33 concentrations (33.89 ± 4.38 Pg/mL) were substantially greater than the healthy group (20.66 ± 2.20 Pg/mL, P<0.02). Pre-treatment expression of IL-33 and ST2 mRNA (1.79 ± 0.18 and 1.42 ± 0.18) was also significantly higher than those in the healthy group (1.00 ± 0.10 and 1.00 ± 0.09; P<0.001 and P<0.05, respectively). After chemotherapy, serum IL-33 concentrations (22.40 ± 2.60 Pg/mL) and mRNA expression of IL-33 (0.91 ± 0.15) were significantly reduced compared to pre-treatment levels (P<0.04 and P<0.001, respectively). There were no notable differences in serum IL-33 levels or mRNA expression of IL-33 and ST2 between controls and treated patients (P<0.61, P<0.63, and P<0.48, respectively).   Conclusion: Greater expression of IL-33 and ST2 was observed in B-ALL patients, which were decreased at the end of a therapy course.</div>   Acute lymphocytic leukemia, Interlukine-33, Suppression 543 553 http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-1170-1&slc_lang=en&sid=1 Marzieh Motaghi Marzieh Motaghi 0000-0002-1455-0463 Yes Department of Hematology and Laboratory Sciences, Para-Medicine School, Kerman University of Medical Sciences, Kerman, Iran Department of Hematology and Laboratory Sciences, Para-Medicine School, Kerman University of Medical Sciences, Kerman, Iran Aida Norouzi Aida Norouzi 0000-0001-8920-8649 No Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran Nazanin Chatrabnous Nazanin Chatrabnous 0000-0002-5103-2163 No Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Abdollah Jafarzadeh Abdollah Jafarzadeh Jafarzadeh14@yahoo.com 0000-0002-8180-0602 No Department of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran Department of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran